	Application No.	Applicant(s)
Notice of Allowability	10/538,310	LANDRY ET AL.
	Examiner	Art Unit
	Maury Audet	1654
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308. 1. This communication is responsive to 8/27/07.		
2. The allowed claim(s) is/are <u>14,16-18,28,30 and 31</u> .		
 3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this national stage application from the 		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)		
1. Notice of References Cited (PTO-892)	5. Notice of Informal P	atent Application
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	 Interview Summary Paper No./Mail Dat 	
3. Information Disclosure Statements (PTO/SB/08),	7. 🛛 Examiner's Amendo	nent/Comment
Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. 🛭 Examiner's Statemé	ent of Reasons for Allowance
	9. Other	

Application/Control Number: 10/538,310

Art Unit: 1654

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given by John White, Applicant's Representative, on 10/1/07.

IN THE CLAIMS

In claim 14, line 2, the entire phrase beginning with "which" has been deleted and -- wherein said peptide is selected from the group consisting of SEQ ID NOS: 1-11-- inserted.

In claim 16, line 1, the entire phrase beginning with "length" has been deleted, and --is SEQ ID NO: 1-- inserted.

Claim 31 has been amended in it's entirety to now read:

31. (Currently Amended) An article of manufacture comprising a peptide of claim 14, wherein said peptide is affixed to a solid substrate.

Claims 25-26 have been cancelled without prejudice.

Reasons for Allowance

The following is an examiner's statement of reasons for allowance:

The prior art of record does not reasonably teach or suggest products comprising peptides selected from the group consisting of any of SEQ ID NOS: 1-11. The amendment of the claims, namely the transition phrase to distinctly claim these peptides, has also overcome all rejections of record.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

Claims 14, 16-18, 28, and 30-31 are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maury Audet whose telephone number is 571-272-0960. The examiner can normally be reached on M-Th. 7AM-5:30PM (10 Hrs.).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang can be reached on 571-272-0562. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/538,310 Page 4

Art Unit: 1654

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

MA, 09/30/2007

Cold (8 8 Cook and Co